-+ 0.00%
-+ 0.00%
-+ 0.00%

Rallybio swings to Q2 net income of $43.67 million; operating loss narrows to $5.65 million

PUBT·08/06/2026 12:05:06
Listen to the news
Rallybio swings to Q2 net income of $43.67 million; operating loss narrows to $5.65 million
  • Rallybio posted GAAP net income of USD 43.67 million for the quarter ended June 30, 2026, swinging from a net loss of USD 9.7 million a year earlier.
  • GAAP operating loss narrowed 43.8% to USD 5.65 million, while revenue fell to no revenue from USD 212,000.
  • GAAP other income rose to USD 50.64 million from USD 641,000, driven by a USD 50 million termination fee tied to the canceled Candid deal.
  • Cash and cash equivalents totaled USD 92.8 million as of June 30, 2026; management expects this to fund operations for at least 12 months beyond the filing.
  • Rallybio is pursuing a merger with Avenzo, alongside a planned USD 215 million concurrent financing, and expects to rename the combined company Avenzo Therapeutics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-053880), on August 06, 2026, and is solely responsible for the information contained therein.